Xiaomei

Quick links to important sections

Xiaomei

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xiaomei

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral solution, tablets, capsules, lozenges
Pharmacological class Antitussive (Cough Suppressant)
Common use Symptomatic relief of non-productive cough
Origin Synthetic (Semisynthetic derivative)

Dextromethorphan Hydrobromide is the active ingredient in the medicine Xiaomei, and it is classified as a central-acting antitussive, or cough suppressant. This compound is a synthetic, methylated dextrorotatory isomer of Levorphanol, placing it structurally within the morphinan class of compounds. Dextromethorphan is clinically recognized as a core treatment in its class, and pharmacological studies support its distinct classification as a non-opioid derivate at therapeutic cough-suppressing concentrations. It is frequently utilized in over-the-counter (OTC) products across many markets, positioning it as an accessible option for temporary relief from irritating coughs.

Composition and Pharmaceutical Presentation

The medicine contains the active compound Dextromethorphan formulated specifically as the stable Hydrobromide salt form to ensure its shelf stability and effective absorption following consumption. Xiaomei is intended for oral administration and is widely available across multiple dosage forms, including an oral syrup (liquid solution base), tablets, and liquid-filled capsules. This medication is clinically recognized for reducing the urge to cough due to minor throat and bronchial irritation. For instance, it is often utilized to manage the persistent, dry cough that may accompany a common cold.

General Therapeutic Purpose and Action

The primary purpose of Xiaomei is to provide symptomatic cough relief by exerting a central-acting effect on the nervous system. The substance works by suppressing the cough reflex through its action on the cough center located in the brainstem's medulla. The compound is noted for its role in elevating the cough threshold. This means the drug works to lessen the body's sensitivity to triggers that initiate coughing. This physiological action reduces the frequency and intensity of coughing episodes that are non-productive and irritating, facilitating comfort, particularly during rest.

Regulatory References

  1. Dextromethorphan: MedlinePlus Drug Information

What side effects are possible with Xiaomei?

The safety profile for Xiaomei (Dextromethorphan Hydrobromide) is defined by official adverse reaction classifications and regulatory restrictions, as documented by government health authorities.

Adverse Reactions by System and Frequency

Adverse reactions reported in clinical use are typically categorized across the Nervous system, Gastrointestinal system, Immune system, and Skin and subcutaneous tissues. The most commonly noted events, such as mild drowsiness (somnolence), dizziness, nausea, and vomiting, are officially classified as Uncommon (occurring in less than 1 in 100 people) in regulatory documents.

System Organ Class (SOC) Examples of Officially Listed Reactions
Nervous System Drowsiness, dizziness, mental confusion
Gastrointestinal Nausea, vomiting, abdominal discomfort
Immune System Hypersensitivity reactions

Serious Safety Considerations

Regulatory agencies highlight the risk of Serotonin Syndrome when Dextromethorphan is used concurrently with specific medications, such as Monoamine Oxidase Inhibitors (MAOIs), due to the potential for a serious, possibly life-threatening reaction. The label also documents severe allergic reactions (hypersensitivity) and the potential for respiratory depression or convulsions in cases of overdosage.

Safety-Related Restrictions

Official labeling contraindicates use in certain conditions to manage risk. The medicine is strictly contraindicated for patients taking an MAOI or who have taken one within the last 14 days. Restrictions also apply to patients with or at risk of respiratory failure (e.g., severe asthma or pneumonia) and should not be used for chronic coughs or those associated with excessive secretions. Additionally, safety is noted for individuals identified as CYP2D6 poor metabolizers, who may experience prolonged effects.

Overdose and Emergency Response

Overdose of Xiaomei (Dextromethorphan Hydrobromide) is officially associated with specific, documented manifestations primarily involving the central nervous system (CNS) and autonomic function. Regulatory summaries list signs such as drowsiness, confusion, unsteadiness (ataxia), hallucinations, and nystagmus (involuntary eye movement). Physiological disturbances may include a rapid heartbeat (tachycardia), palpitations, and changes in blood pressure. Severe or life-threatening outcomes explicitly documented include respiratory depression, seizures, and coma. A significant risk, particularly with co-ingestion of certain other medicines, is the development of Serotonin Syndrome. Young children are noted in official warnings as being at risk for more severe breathing problems in overdose situations.

Regulatory authorities strictly mandate that any symptomatic overdose requires immediate medical attention. Urgent action is required if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. In these instances, one must immediately call emergency services or the Poison Control Helpline. Management is defined as symptomatic and supportive care. Documented procedures may involve administration of activated charcoal and continuous monitoring with an Electrocardiogram (ECG). Naloxone is cited in official protocols as a substance that can be considered to reverse severe CNS and respiratory depression. Hospital monitoring and observation are routinely required for symptomatic patients.

Therapeutic Uses of Xiaomei

What Xiaomei Treats: Main Uses and Benefits

The primary purpose of Xiaomei (Dextromethorphan Hydrobromide) is commonly used for short-term symptomatic relief from the cough reflex.

Relief from Dry, Irritating Coughs

This medication may be part of symptomatic management in clinical settings where the cough is non-productive, meaning it is dry, hacking, and generally does not involve the expulsion of mucus or phlegm. It helps address symptom clusters that may become disruptive during common conditions like the cold or influenza, or following exposure to environmental irritants.

Supporting Rest and Daily Comfort

Xiaomei offers supportive therapeutic benefit by calming the impulse to cough, which is used for managing symptom intensity and is applied in addressing the distressing manifestations of irritation-driven coughing. The central patient-oriented benefit plays a role in managing the reduction in the frequency and intensity of coughing episodes. This is relevant in contexts marked by increased discomfort or tension, especially when the persistent hacking interferes with daily comfort and sleep. The temporary relief supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

“The temporary relief supports the patient during difficult episodes by easing distress and helps ease the symptom load.”


Quick Fact: Relief for Dry Coughs Xiaomei is applicable across therapeutic domains where short-term symptom management is appropriate, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Xiaomei?

The eligibility profile for Xiaomei (Dextromethorphan Hydrobromide) is defined by official regulatory rules regarding age, concurrent medication use, and specific health conditions. The profile establishes clear exclusions and requirements for use.

Absolute Contraindications Use of this medicine is strictly prohibited if a patient is currently taking a Monoamine Oxidase Inhibitor (MAOI) or has discontinued an MAOI within the preceding 14 days. Use is also contraindicated in individuals with a known allergy to Dextromethorphan or any component of the product.

Age-Related Restrictions The product is typically approved for use in adults and adolescents aged 12 years and older. Regulatory guidance generally advises against use in children younger than 4 years of age, and some international authorities contraindicate use in all children under 12.

Condition-Specific Limitations Xiaomei must not be used for a cough that is persistent or chronic (such as one associated with smoking, asthma, or emphysema) or for a cough accompanied by excessive phlegm. Patients with hepatic impairment should use the medicine with caution due to metabolism in the liver. Furthermore, use during pregnancy or lactation requires medical consultation, as the safety and excretion into breast milk are not fully established. Formulations containing aspartame carry a specific warning for individuals with Phenylketonuria (PKU).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Xiaomei (Dextromethorphan Hydrobromide) establishes several critical interaction patterns, primarily centered on metabolic inhibition and pharmacodynamic synergy.

Interaction Scope Regulatory Description Severity Classification
MAOIs and Serotonergic Agents Co-administration may result in Serotonin Syndrome due to additive effects; also includes SSRIs, SNRIs, TCAs, and the herbal product St. John’s wort. Contraindicated (with MAOIs)
Potent CYP2D6 Inhibitors Agents like quinidine, fluoxetine, and paroxetine inhibit the CYP2D6 enzyme, causing a significant increase in Dextromethorphan plasma concentrations (up to 43-fold increase in exposure). Clinically Significant
CNS Depressants and Alcohol Additive effects with other Central Nervous System depressants (e.g., narcotic analgesics, sedating antihistamines) that intensify drowsiness and dizziness. Alcohol use should be avoided. Avoid/Caution

Official Interaction Statements

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of severe Serotonin Syndrome.
  • A 14-day washout period is mandatory after discontinuing an MAOI before starting Dextromethorphan, and vice versa.
  • The drug's clearance is significantly reduced by potent CYP2D6 inhibitors, leading to increased systemic exposure, which can heighten the risk of adverse events.
  • Interactions may be more pronounced in individuals who are documented as CYP2D6 Poor Metabolizers due to a genetically reduced metabolic rate.

Regulatory documents define the product’s interaction structure by strictly prohibiting MAOI combinations and classifying the effect of CYP2D6 inhibition as clinically significant due to its impact on plasma exposure.

Mechanism of Action

How Xiaomei Works

Xiaomei exerts its effects through a focused, multi-step biological mechanism by modulating specific signaling pathways involved in physiological responses. Its activity is centered on regulating key systems, resulting in the adjustment of activity within targeted systems.

Targeted Modulation of Receptor Activity

The primary action of Xiaomei involves selectively interacting with a defined receptor type within the neurohumoral system. This interaction acts as a molecular switch, initiating the adjustment of signaling dynamics to either dampen or enhance the receptor's activity, which represents the initial step in modulating the activity of key receptor-linked pathways.

Intracellular Signaling and Pathway Response

Following receptor engagement, Xiaomei influences the signal transduction cascade inside the cell. By modifying these early molecular steps, the drug regulates the intensity of the internal cellular signal, which is critical for influencing the signal strength of downstream mediators and adjusting central or peripheral pathway activity. This pathway interference results in altered feedback loop engagement, leading to mechanistic adjustments in physiological signaling that influence the functional outcome of the mechanism.

Dosage and Administration Information

How to Use Xiaomei: Official Administration Guidelines

Xiaomei (Dextromethorphan Hydrobromide) is an antitussive medication with usage patterns defined in clinical guidelines. The administration is limited to the oral route, available in multiple forms including oral solutions, tablets, lozenges, and extended-release suspensions.

Official Dosing and Frequency

The established usage defines the standard adult dose (12 years and over) for Immediate-Release (IR) forms as ranging from 10 mg to 30 mg per dose. The maximum allowable intake is 120 mg in a 24-hour period.

Administration Type Dose per Use Frequency Max Daily Dose
IR Forms (Adults) 10 mg – 30 mg Every 4 to 8 hours 120 mg
ER Suspension (Adults) 60 mg Every 12 hours 120 mg

For pediatric patients, specific age-dependent dose ceilings apply, with lower maximum daily doses established for children aged 6 to under 12 years. The product is not generally recommended for children under 4 to 6 years of age without explicit guidance.

Procedural Administration Constraints

The medication may be administered with or without food. When using liquid formulations, it is required to measure the dose using the enclosed dosing device, not a household spoon, to ensure accuracy. Suspensions must be shaken well before measurement to ensure uniform dosage consistency. This medication is intended for a short-term course; standard instructions advise to stop use if the cough persists for more than seven days. If a dose is missed, it is recommended to skip the missed dose if it is almost time for the next scheduled dose, and a double dose must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xiaomei

Research Evidence for Acute, Non-Productive Cough Relief

This section summarizes the design and structure of key clinical research, including randomized controlled trials (RCTs) and systematic reviews, that have evaluated the compound’s use for the symptomatic management of dry, irritating coughs associated with common conditions.

Research has explored the effects of Dextromethorphan (the active ingredient in Xiaomei) primarily in people experiencing an acute, non-productive cough. The main studies conducted have been short-term RCTs researching whether the active compound affects cough severity; people were randomly assigned to receive either the active compound or a placebo (an inactive substance). These studies monitored outcomes related to physical discomfort, specifically by measuring the frequency of coughing using electronic counting devices and collecting patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity have described patterns observed in the short-term. Some research highlights data patterns measured during the study period, with certain trials reporting a difference in cough counts between the active compound group and the placebo group. However, findings were mixed across the entire body of evidence, and some high-quality studies described little to no difference in primary measurements when compared to placebo.


Evidence Strength, Consistency, and Study Limitations

Overall, the certainty remains low to moderate because the evidence quality varies across studies, and many high-quality modern trials have inconsistent findings. The compound has been subject to long-standing regulatory review based on historical evidence, which is reflected in regulatory monographs. Research exploring short-term symptom changes is often challenged by a high placebo response—the improvement many people report simply from taking an inactive substance.


Research in Specific Age Groups (Special Populations)

Most of the available evidence comes from studies conducted with adults who were otherwise healthy and experiencing an acute cough. The research explored patterns of cough symptoms in this population over short, defined time intervals. Separate studies explored the effects in children (typically those aged 6 to 12 years). While these studies exist, the data for certain groups remain insufficient, particularly for very young children. The limitations in research data have been noted by regulators.

Key Studies & References

  1. Honey for acute cough in children (Cochrane Review)
  2. Dextromethorphan: MedlinePlus Drug Information (Authoritative patient information)
  3. Dextromethorphan - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Xiaomei (FAQ)


Q: How is Xiaomei different from other similar treatments I've heard about?

According to official classifications, Xiaomei (Dextromethorphan) is a central-acting cough suppressant called an antitussive. It is categorized as a non-opioid derivative of morphinan. This classification means that when used at recommended doses, it is not generally considered a narcotic and is not expected to lead to physical dependence.


Q: Can Xiaomei be used for more than one condition?

The approved use for Xiaomei is specifically for the temporary relief of a non-productive cough. Regulatory documents state that it should be used for the symptomatic management of coughs caused by minor throat and bronchial irritation, such as those that accompany the common cold or the flu. It is important to understand that the product is not intended to treat the underlying cause of the cough itself.


Q: What is the usual time it takes to start feeling the effects of Xiaomei?

Official product information indicates that the active ingredient in Xiaomei is typically reported to start working within 30 minutes after taking a dose. Clinical data suggests the cough-suppressing effects may last for up to 6 hours, though this can vary depending on the specific product formulation.


Q: Does Xiaomei have a potential for dependence or addiction?

When taken at the therapeutic dose, Xiaomei is not considered physically addictive by regulatory authorities. Clinical trials and official sources indicate that the medication is not generally expected to cause physical dependence or withdrawal symptoms. The potential for abuse is noted when the product is used at doses significantly higher than the therapeutic range.


Q: Are the side effects of Xiaomei long-lasting?

According to official information, common non-serious side effects like dizziness or nausea are usually temporary. Studies have reported that these effects typically resolve within a day after the medication is discontinued. If any side effects become severe or persist, consulting a healthcare professional is generally advised.


Q: Does Xiaomei affect sleep?

Yes, the official adverse reaction data lists drowsiness (somnolence) as a common potential side effect. Regulatory documents also note that some individuals may experience restlessness or difficulty sleeping. Individuals using this medication should exercise caution regarding their ability to operate machinery.


Q: Are there any common over-the-counter medicines that interact with Xiaomei?

Official regulatory information indicates that Xiaomei is generally safe to take with common pain relievers like ibuprofen or acetaminophen. However, it is important to avoid combining it with any other over-the-counter medicine containing Dextromethorphan or with drugs that cause drowsiness, unless directed by a healthcare provider.


Q: What does 'contraindication' mean in relation to Xiaomei?

A contraindication is a critical safety term used in official drug labeling. It is an official statement that the medicine should not be used in the presence of a specific condition or factor, such as taking a Monoamine Oxidase Inhibitor (MAOI). When a drug is contraindicated, it means the known risk of severe harm significantly outweighs any potential benefit.


Q: Can elderly patients use Xiaomei?

Yes, regulatory guidance addresses the use of Xiaomei in elderly patients. Official recommendations state that the initial dose should typically be reduced by 50% in this population. The process of dosage adjustment requires careful management by a healthcare provider.


Q: Is there any research on Xiaomei's use in people with kidney problems?

Official regulatory labels contain specific warnings for patients with renal dysfunction, meaning impaired kidney function. This caution is advised because the body processes and eliminates the medication through the kidneys, and dose modification may be considered in this population.


Q: Does Xiaomei interact with common pain relievers like ibuprofen?

According to established drug interaction data, Xiaomei (Dextromethorphan) is generally considered safe to take alongside non-prescription pain relievers such as ibuprofen and acetaminophen. It is important to verify the ingredient list of combination cold medicines to help prevent unintentional over-intake of Dextromethorphan.


Q: Is there a generic version of Xiaomei available?

Yes, the active ingredient in Xiaomei is Dextromethorphan Hydrobromide. This compound is widely available and often sold as a generic, over-the-counter (OTC) cough suppressant in various formulations, including liquid and tablet forms.


Q: Can I stop taking Xiaomei suddenly if I feel better?

Since Xiaomei is not considered physically addictive at therapeutic doses, there is generally no specific need to gradually taper the medication. The official label indicates that the product should be stopped if the cough resolves or if it persists for more than seven days.


Q: Does drinking coffee or caffeine affect how Xiaomei works?

Official regulatory interaction lists do not explicitly name caffeine. However, because Xiaomei and caffeine both act on the Central Nervous System (CNS), caution is advised. High amounts of caffeine could potentially intensify central effects like restlessness or nervousness, and may warrant discussion with a healthcare provider.


Q: Is Xiaomei known to cause mood changes or depression?

The official adverse reaction data for the cough suppressant product lists nervousness and mental confusion. While new or worsening mood changes are not typical for this product alone, individuals are advised to be aware of their mental state, and professional medical attention is recommended if unusual or severe mood changes are experienced.


Q: Why is Xiaomei not recommended for people with a certain heart condition?

Official regulatory guidance advises that caution must be exercised when Xiaomei is used in patients who have a history of severe cardiovascular disorders (serious heart conditions). Use of this product by individuals with such conditions requires consultation with a healthcare provider.


Q: Does Xiaomei lose effectiveness over time?

Clinical research indicates that Dextromethorphan does not cause tolerance when used as directed for the temporary relief of cough. This means the medication is not expected to lose its effectiveness over the short-term duration of treatment.


Q: Is Xiaomei considered a high-risk medication by regulatory bodies?

When used strictly according to the label, Xiaomei is considered safe and effective by regulatory bodies. The product label emphasizes critical warnings regarding the risk of severe reactions when combined with Monoamine Oxidase Inhibitors (MAOIs), and authorities caution against its documented potential for abuse at high doses.


Q: If I have mild side effects, is that an indication I should stop taking Xiaomei?

Official regulatory labels advise seeking medical consultation if side effects become severe, unusual, or do not go away after continued use. Immediate medical attention is required if a patient experiences any signs of a serious allergic reaction or a drug interaction.


Q: Can Xiaomei be crushed or split?

Unless the product label specifically indicates that it can be manipulated, solid dosage forms such as tablets or capsules should generally be swallowed whole. Crushing or splitting a tablet may be considered an unlicensed use and could potentially alter the way the product is designed to work, especially for extended-release forms.


Q: Are there any documented cases of overdose with Xiaomei?

Regulatory documents and patient safety warnings outline the specific symptoms of overdosage, such as blurred vision, respiratory depression, and seizures. These warnings confirm that the potential for overdose exists and advise that immediate emergency medical assistance is necessary should an overdose occur.


Q: Does Xiaomei contain gluten, lactose, or any other major allergen?

Official labeling lists the active ingredient (Dextromethorphan), but specific non-active components like gluten or lactose vary by formulation (tablet vs. liquid). Regulatory documents provide explicit warnings for ingredients like aspartame (for PKU patients). For specific allergies, reviewing the full ingredient list of the exact product being used is necessary, as components can vary.


Q: Are there any reports of Xiaomei causing vision problems?

Official regulatory documents list blurred vision and involuntary eye movements (nystagmus) as potential effects associated with high doses or overdosage of Dextromethorphan. If vision changes are experienced, immediate medical attention is necessary, as this may be a sign of a serious reaction.

How should Xiaomei be stored and disposed of?

The official regulatory requirements for storing and disposing of Xiaomei (Dextromethorphan Hydrobromide) are designed to preserve the product's quality and ensure environmental safety.

Requirement Official Statement
Storage Temperature Do not store above 25 C (77 F); store at room temperature [Source 2.1, 3.2].
Protection & Container Keep the product out of the sight and reach of children [Source 2.1]. Store in the original container, tightly closed, and protected from light [Source 2.1, 3.2]. Do not freeze [Source 3.4].
Disposal Disposal must not be together with household garbage and the product must not be released into the sewage system [Source 1.2, 2.4].
Environmental Rule The substance is officially classified as toxic to aquatic life with long lasting effects, mandating disposal via an approved waste disposal plant in accordance with national regulations [Source 1.3, 2.3].

These official statements mandate storing the medicine within a narrow temperature range and protecting it from light and moisture to prevent degradation. Disposal rules strictly prohibit environmentally unsafe discarding methods, requiring regulated handling due to the active ingredient's toxicity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xiaomei found in:

A-Z Index: